About Fennec Pharmaceuticals (NASDAQ:FENC)
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FENC
CUSIPN/A
Phone919-636-4530
Debt
Debt-to-Equity RatioN/A
Current Ratio17.32%
Quick Ratio17.32%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.68 per share
Price / Book7.94
Profitability
EPS (Most Recent Fiscal Year)($0.47)
Net Income$-7,040,000.00
Net MarginsN/A
Return on Equity-58.56%
Return on Assets-54.40%
Miscellaneous
Employees3
Outstanding Shares18,470,000
Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions
What is Fennec Pharmaceuticals' stock symbol?
Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."
How were Fennec Pharmaceuticals' earnings last quarter?
Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its earnings results on Monday, March, 26th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.01. View Fennec Pharmaceuticals' Earnings History.
When is Fennec Pharmaceuticals' next earnings date?
What price target have analysts set for FENC?
3 Wall Street analysts have issued 1-year price objectives for Fennec Pharmaceuticals' stock. Their predictions range from $17.00 to $22.00. On average, they anticipate Fennec Pharmaceuticals' share price to reach $19.00 in the next year. View Analyst Ratings for Fennec Pharmaceuticals.
Who are some of Fennec Pharmaceuticals' key competitors?
Some companies that are related to Fennec Pharmaceuticals include BioCryst Pharmaceuticals (BCRX), PDL Biopharma (PDLI), Vericel (VCEL), Nightstar Therapeutics (NITE), Agenus (AGEN), Solid Biosciences (SLDB), Idera Pharmaceuticals (IDRA), Cellular Biomedicine (CBMG), Adverum Biotechnologies (ADVM), NantKwest (NK), Allena Pharmaceuticals (ALNA), Osiris Therapeutics (OSIR), NanoString Technologies (NSTG), Arsanis (ASNS), ADMA Biologics (ADMA), Compugen (CGEN), Pluristem Therapeutics (PSTI) and Organovo (ONVO).
Who are Fennec Pharmaceuticals' key executives?
Fennec Pharmaceuticals' management team includes the folowing people:
- Khalid Islam Ph.D., Chairman of the Board (Age 61)
- Rostislav C. Raykov, Chief Executive Officer, Director (Age 39)
- Robert C. Andrade, Chief Financial Officer (Age 39)
- Marco Maria Brughera, Director (Age 60)
- Adrian J. Haigh, Independent Director (Age 56)
- Chris A. Rallis, Independent Director (Age 61)
- Steven D. Skolsky, Independent Director (Age 61)
Has Fennec Pharmaceuticals been receiving favorable news coverage?
News coverage about FENC stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fennec Pharmaceuticals earned a media sentiment score of 0.19 on Accern's scale. They also gave news stories about the company an impact score of 46.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Fennec Pharmaceuticals?
Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fennec Pharmaceuticals' stock price today?
One share of FENC stock can currently be purchased for approximately $13.34.
How big of a company is Fennec Pharmaceuticals?
Fennec Pharmaceuticals has a market capitalization of $248.17 million. The company earns $-7,040,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Fennec Pharmaceuticals employs 3 workers across the globe.
How can I contact Fennec Pharmaceuticals?
Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.
MarketBeat Community Rating for Fennec Pharmaceuticals (FENC)
MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote "Outperform" if you believe FENC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Fennec Pharmaceuticals (NASDAQ:FENC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Fennec Pharmaceuticals in the last 12 months. Their average twelve-month price target is $19.00, suggesting that the stock has a possible upside of 42.43%. The high price target for FENC is $22.00 and the low price target for FENC is $17.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.00 | $18.3333 | $22.00 | N/A |
| Price Target Upside: | 42.43% upside | 74.60% upside | 126.80% upside | N/A |
Fennec Pharmaceuticals (NASDAQ:FENC) Consensus Price Target History
Fennec Pharmaceuticals (NASDAQ:FENC) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 4/2/2018 | HC Wainwright | Reiterated Rating | Buy | $18.00 | Low |  |
| 3/12/2018 | Wedbush | Initiated Coverage | Outperform | $17.00 | High | |
| 11/29/2017 | Laidlaw | Initiated Coverage | Buy -> Buy | $22.00 | High | |
(Data available from 4/21/2016 forward)
Fennec Pharmaceuticals (NASDAQ:FENC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Fennec Pharmaceuticals (NASDAQ FENC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.70%
Institutional Ownership Percentage: 38.80%
Fennec Pharmaceuticals (NASDAQ FENC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/28/2018 | Manchester Management Pr, Llc | Major Shareholder | Sell | 914,745 | $10.61 | $9,705,444.45 | | |
| 12/12/2017 | Spa Essetifin | Major Shareholder | Buy | 294,115 | $8.50 | $2,499,977.50 | | |
(Data available from 1/1/2013 forward)
Fennec Pharmaceuticals (NASDAQ FENC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Set $17.50 Price Target for Fennec Pharmaceuticals Inc (FENC)
www.americanbankingnews.com - April 16 at 9:25 AM |
| Zacks: Brokerages Expect Fennec Pharmaceuticals Inc (FENC) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 12 at 1:25 PM |
| Fennec Pharmaceuticals (FENC) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 3 at 3:37 PM |
| Fennec Pharmaceuticals (FENC) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - April 2 at 8:03 AM |
| Zacks: Fennec Pharmaceuticals Inc (FENC) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 30 at 7:42 AM |
| Equities Analysts Issue Forecasts for Fennec Pharmaceuticals Inc's Q1 2018 Earnings (FENC)
www.americanbankingnews.com - March 30 at 6:46 AM |
| Fennec Pharmaceuticals Inc (FENC) Major Shareholder Sells $9,705,444.45 in Stock
www.americanbankingnews.com - March 29 at 10:10 PM |
 | Fennec Pharmaceuticals (FENC) Granted Breakthrough Therapy Designation by FDA for PEDMARK
www.streetinsider.com - March 29 at 4:17 PM |
| FY2020 EPS Estimates for Fennec Pharmaceuticals Inc Reduced by Wedbush (FENC)
www.americanbankingnews.com - March 29 at 8:46 AM |
 | Fennec Flat After FDA Nod for PEDMARK
www.baystreet.ca - March 27 at 4:14 PM |
| Fennec Pharmaceuticals Inc. (FENC) PT Maintained at $17 at Wedbush on PEDMARK Update; 'Approval Outlook Improves'
www.streetinsider.com - March 27 at 4:14 PM |
 | Fennec Pharmaceuticals receives Breakthrough Therapy designation by FDA for PEDMARK
seekingalpha.com - March 27 at 10:08 AM |
 | Fennec Pharmaceuticals Receives Breakthrough Therapy Designation by FDA for PEDMARK™
finance.yahoo.com - March 27 at 10:08 AM |
| Fennec's stock soars further after PEDMARK receives 'breakthrough therapy' designation
finance.yahoo.com - March 27 at 10:08 AM |
| Fennec receives new FDA designation as company readies for commercial launch
finance.yahoo.com - March 27 at 10:08 AM |
| Fennec Pharmaceuticals Inc (FENC) Expected to Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - March 26 at 3:26 PM |
 | Fennec Provides Business Update and Announces...
www.benzinga.com - March 26 at 10:09 AM |
| Fennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results
finance.yahoo.com - March 26 at 10:09 AM |
| Fennec Pharmaceuticals (FENC) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - March 25 at 6:25 PM |
| 3 Things In Biotech, March 22: Sun Is In, Fennec Moving Fast, Fortress Heads Out
seekingalpha.com - March 24 at 4:11 PM |
| Fennec Pharmaceuticals (FENC) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 22 at 2:27 PM |
| Good news for Fennec ahead of FDA submission
finance.yahoo.com - March 21 at 4:12 PM |
| Fennec Pharmaceuticals (FENC) and AzurRx BioPharma (AZRX) Financial Comparison
www.americanbankingnews.com - March 18 at 9:12 PM |
| Brokers Issue Forecasts for Fennec Pharmaceuticals Inc's FY2017 Earnings (FENC)
www.americanbankingnews.com - March 15 at 7:25 AM |
| Zacks: Fennec Pharmaceuticals Inc (FENC) Given $16.50 Consensus Target Price by Analysts
www.americanbankingnews.com - March 15 at 5:23 AM |
| Fennec Pharmaceuticals (FENC) Receives New Coverage from Analysts at Wedbush
www.americanbankingnews.com - March 12 at 9:22 PM |
| Zacks: Analysts Expect Fennec Pharmaceuticals Inc (FENC) to Announce -$0.15 Earnings Per Share
www.americanbankingnews.com - March 9 at 12:42 PM |
| Analysts Anticipate Fennec Pharmaceuticals Inc (FENC) to Post ($0.15) Earnings Per Share
www.americanbankingnews.com - March 9 at 1:12 AM |
| Critical Analysis: Fennec Pharmaceuticals (FENC) versus Its Competitors
www.americanbankingnews.com - February 23 at 11:12 PM |
| Fennec Pharmaceuticals Inc (FENC) Given $16.00 Consensus Price Target by Analysts
www.americanbankingnews.com - February 22 at 11:44 AM |
| Fennec Pharmaceuticals (FENC) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - February 20 at 11:30 AM |
| ValuEngine Lowers Fennec Pharmaceuticals (FENC) to Sell
www.americanbankingnews.com - December 24 at 6:26 PM |
| Fennec Pharmaceuticals Inc (FENC) Major Shareholder Spa Essetifin Acquires 294,115 Shares
www.americanbankingnews.com - December 14 at 5:34 PM |
| Fennec’s $20M offering primes company for 2019 commercial launch
finance.yahoo.com - December 11 at 9:28 AM |
| Fennec Pharmaceuticals (FENC) Prices 2.35M Common Stock Offering at $8.50/Share
www.streetinsider.com - December 10 at 8:50 AM |
| Adherex Technologies (FENC) Now Covered by Analysts at Laidlaw
www.americanbankingnews.com - November 29 at 1:00 PM |
 | Mitsubishi Connect Provides Enriched, More Personalized Driving Experience
www.businesswire.com - November 28 at 5:55 PM |
| Adherex Technologies Inc. (FENC) Announces Earnings Results
www.americanbankingnews.com - November 14 at 9:56 AM |
| Cirrus Logic (CRUS) Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - November 3 at 12:24 PM |
| Symantec (SYMC) Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - November 2 at 12:46 AM |
 | The 5 Best Growth Stocks in Tech for 2018
www.nasdaq.com - October 20 at 12:24 AM |
| Fennec banks positive results on heels of move to Nasdaq
finance.yahoo.com - October 19 at 7:23 PM |
| Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting
finance.yahoo.com - October 16 at 7:03 PM |
| Fennec to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017 in New York City
finance.yahoo.com - September 20 at 7:37 PM |
 | Safety Dynamics, Beeper Communications and Mantaro Networks Sign Strategic Technology Alliance to Support Public Safety and Gunshot Detection
www.bizjournals.com - September 20 at 2:44 AM |
| IIROC Trade Resumption - Fennec Pharmaceuticals Inc.
finance.yahoo.com - September 19 at 4:41 PM |
Fennec Pharmaceuticals (NASDAQ:FENC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Fennec Pharmaceuticals (NASDAQ:FENC) Income Statement, Balance Sheet and Cash Flow Statement
Fennec Pharmaceuticals (NASDAQ FENC) Stock Chart for Saturday, April, 21, 2018
Loading chart…
